Industry Insights
Sep 22, 2026 · 1 min read · 64,191 views
Ziopharm rebrands to Alaunos, closes Boston office with new CEO at the reins
E
Ethan Cole
Editorial · Sep 22, 2026
A little over a year after facing an activist attack that saw former CEO Laurence Cooper survive but retire a few months later, Ziopharm Oncology will undergo a rebranding and
← Previous
Merck plans a sac-TMT combo trial with Keytruda as patent cliff looms
Next →
UK government committees call for probe into US pharma deal
